Program
brepocitinib
Also written as “PF-06700841”, “Brepocitinib” and “Oral Brepocitinib”.
Its studies are mostly in Psoriasis · Dermatomyositis · Sarcoidosis · Lichen Planus · Uveitis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 200 open or running | phase 2since Nov 4, 2016 | Nov 18, 2014 | none ahead |
| Priovant Therapeutics | 52 open or running | phase 3since Jun 24, 2022 | Jun 24, 2022 | Dec 31, 2028phase 3 · NCT06978725 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Nov 18, 2014.
- Dec 6, 2018Phase 1 study in Healthy Male SubjectsPfizer · NCT03770039 · 6 enrolled · Netherlands
- Feb 15, 20192 phase 2 studiesPfizer · NCT03845517, NCT03850483
- Mar 20, 2019Phase 1 study in HealthyPfizer · NCT03916250 · 20 enrolled · Japan
- Mar 20, 2019Phase 2 study in Dermatitis, AtopicPfizer · NCT03903822 · 292 enrolled · United States, Australia, Bulgaria and more
- May 15, 2019Phase 2 study in Arthritis, PsoriaticPfizer · NCT03963401 · 219 enrolled · Australia, Bulgaria, Czechia and more
- Sep 12, 2019Phase 1 study in Heathy ParticipantsPfizer · NCT04090047 · 12 enrolled · United States
- Sep 15, 2019Phase 2 study in Hidradenitis SuppurativaPfizer · NCT04092452 · 194 enrolled · United States, Australia, Canada
- Feb 5, 20202 phase 1 studiesPfizer · NCT04260464, NCT04267250
- Sep 25, 2020Phase 1 study in Healthy ParticipantsPfizer · NCT04580797 · 36 enrolled · United States
- Jun 24, 2022Priovant Therapeutics's first study: phase 3 study in DermatomyositisNew to Priovant TherapeuticsPriovant Therapeutics · NCT05437263 · 241 enrolled · United States, Argentina, Belgium and more
- Aug 25, 2022Phase 2 study in UveitisPriovant Therapeutics · NCT05523765 · 26 enrolled · United States
- May 23, 2024Phase 2 study in DermatomyositisPriovant Therapeutics · NCT06433999 · 5 enrolled · United States
- Apr 30, 2025Phase 3 study in SarcoidosisPriovant Therapeutics · NCT06978725 · 168 planned · United States, Australia, United Kingdom
- Apr 3, 2026Phase 3 study in Lichen PlanusPriovant Therapeutics · NCT07532603 · 342 planned · United States, Australia, Canada and more
Ahead
- Dec 31, 2028Primary completion: phase 3 study in Lichen PlanusPriovant Therapeutics · NCT07532603
- Dec 31, 2028Primary completion: phase 3 study in SarcoidosisPriovant Therapeutics · NCT06978725
TargetBeta
“An orally available, selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1) ”NCIt, by rule
“Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| FXS5626 | Fosun Pharma | phase 3 | 3 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07532603Lichen Planus · United States, Australia, Canada and more | 3 | Recruiting | Priovant Therapeutics | Dec 31, 2028 | 342 |
| NCT06978725Sarcoidosis · United States, Australia, United Kingdom | 3 | Recruiting | Priovant Therapeutics | Dec 31, 2028 | 168 |
| NCT06433999Dermatomyositis · United States | 2 | Completed | Priovant Therapeutics | Feb 28, 2025 | 5 |
| NCT05523765Uveitis · United States | 2 | Completed | Priovant Therapeutics | Jul 30, 2024 | 26 |
| NCT05437263Dermatomyositis · United States, Argentina, Belgium and more | 3 | Completed | Priovant Therapeutics | Jul 17, 2025 | 241 |
| NCT04580797Healthy Participants · United States | 1 | Completed | Pfizer | Jan 11, 2021 | 36 |
| NCT04267250Healthy Female Volunteers · United States | 1 | Completed | Pfizer | Nov 6, 2020 | 18 |
| NCT04260464Renal Insufficiency · United States | 1 | Completed | Pfizer | May 4, 2022 | 30 |
| NCT04092452Hidradenitis Suppurativa · United States, Australia, Canada | 2 | Completed | Pfizer | Jan 10, 2022 | 194 |
| NCT04090047Heathy Participants · United States | 1 | Completed | Pfizer | Dec 19, 2019 | 12 |
| NCT03963401Arthritis, Psoriatic · Australia, Bulgaria, Czechia and more | 2 | Completed | Pfizer | Apr 6, 2020 | 219 |
| NCT03916250Healthy · Japan | 1 | Completed | Pfizer | Apr 15, 2019 | 20 |
| NCT03903822Dermatitis, Atopic · United States, Australia, Bulgaria and more | 2 | Completed | Pfizer | May 7, 2020 | 292 |
| NCT03850483Psoriasis · United States, Australia, Bulgaria and more | 2 | Completed | Pfizer | Apr 20, 2021 | 344 |
| NCT03845517Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Completed | Pfizer | Oct 5, 2023 | 350 |
| NCT03770039Healthy Male Subjects · Netherlands | 1 | Completed | Pfizer | Feb 21, 2019 | 6 |
| NCT03765554Healthy Participants · Belgium | 1 | Completed | Pfizer | Apr 3, 2019 | 8 |
| NCT03715829Active Non-segmental Vitiligo · United States, Australia, Belgium and more | 2 | Completed | Pfizer | Feb 5, 2021 | 366 |
| NCT03656952Healthy · Belgium | 1 | Completed | Pfizer | Feb 6, 2019 | 33 |
| NCT03395184Crohn Disease · United States, Australia, Austria and more | 2 | Completed | Pfizer | Oct 19, 2023 | 244 |
| NCT03236493Healthy · Belgium | 1 | Completed | Pfizer | Sep 17, 2017 | 8 |
| NCT02974868Alopecia Areata · United States, Australia, Canada | 2 | Completed | Pfizer | May 15, 2019 | 142 |
| NCT02969018Chronic Plaque Psoriasis · United States, Canada, Poland | 2 | Completed | Pfizer | Mar 2018 | 212 |
| NCT02958865Colitis, Ulcerative · United States, Austria, Bulgaria and more | 2 | Completed | Pfizer | May 10, 2021 | 319 |
| NCT02310750Plaque Psoriasis · United States | 1 | Completed | Pfizer | Jan 2016 | 96 |
How it is read
Names in the registry
- “PF-06700841”, 13 entries
- “Brepocitinib”, 3 entries
- “Oral Brepocitinib”, 2 entries
- “PF-06700841 15 mg”, 1 entry
- “PF-06700841 30 mg”, 1 entry
Codes read as this program: PF06700841.
Conditions, from the studies’ own filings
- Psoriasis, 3 studies
- Dermatomyositis, 2 studies
- Sarcoidosis, 1 study
- Lichen Planus, 1 study
- Uveitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.